Hepatitis C Therapy
Peg-interferon may benefit patients with HCV-related cryoglobulinemia
Published in Health and Medicine Week, July 11th, 2005
According to research from Italy, "the aim of this study is to verify the efficacy and safety of pegylated (peg)-interferon alfa-2b in combination with ribavirin for initial treatment of hepatitis C virus (HCV)-associated mixed cryoglobulinemia. Eighteen patients (7 women and 11 men) affected by mixed cryoglobulinemia were included in the study and treated with peg-interferon alfa-2b 1.0 mcg/kg once a week plus ribavirin (1000 mg daily) for 48 weeks, regardless of the HCV genotype."
"At the end of the treatment HCV-RNA became undetectable in 15 patients (83%) and most patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
More Articles from Health and Medicine Week
- Alzheimer Disease Vaccine
Effects of A-beta immunization in patients with AD in an interrupted trial - Attention Deficit Hyperactivity Disorder
Methylphenidate transdermal system shows promise in children - Health Insurance
National Survey of Children With Special Health Care Needs released - Neuroscience
Autism is not associated with key serotonin transporter gene polymorphisms - Pain Medicine
Age may be key factor in opioid dose escalation - Acetylcholine Receptors
Thalamocortical synapses studied, hypocretin and nicotine responses defined - More from this issue of Health and Medicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
